Abeona Therapeutics (ABEO) Cash from Operations (2011 - 2026)

Abeona Therapeutics' Cash from Operations history runs 16 years deep, the most recent figure standing at 19804000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 7.62% year-over-year to 19804000.0 in Q1 2026; TTM through Mar 2026 was 77728000.0, a 29.81% decrease from a year earlier, with the FY2025 full-year figure at 76326000.0, down 36.26% from the prior year.
• Cash from Operations declined to 19804000.0 in Q1 2026 per ABEO's latest filing, from 17953000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 5746000.0 in Q3 2023 and bottomed at 21187000.0 in Q3 2025.
• The 5-year median for Cash from Operations is 13687000.0 (2022), against an average of 13684529.41.
• Across the five-year window, Cash from Operations surged 53.76% in 2022 and sank 112.91% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 13992000.0 in 2022, then jumped by 34.0% to 9235000.0 in 2023, then tumbled by 79.31% to 16559000.0 in 2024, then slipped by 8.42% to 17953000.0 in 2025, then retreated by 10.31% to 19804000.0 in 2026.
• Per Business Quant, the three latest ABEO Cash from Operations figures stand at 19804000.0 (Q1 2026), 17953000.0 (Q4 2025), and 21187000.0 (Q3 2025).